MedDRA preferred term

Spinal operation: adverse event reports recording this term

11,946 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

11,946
reports recording the term: 0.1% of all reports; 1,356
reports, 12 months to June 2026: 1,304 in the 12 months before; 91.6%
marked serious by the reporter: 57.4% across all reports; 1.4%
record death among outcomes, as reported: 9.1% across all reports

"Spinal operation" is a MedDRA preferred term recorded in 11,946 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,356 reports recorded it in the 12 months to June 2026, close to the 1,304 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 91.6% are marked serious, 1.4% include death among the outcomes and 37.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humira, Rinvoq and Enbrel. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Humira	—	1,092	0.2%
Rinvoq	Janus kinase inhibitor	1,036	1.4%
Enbrel	Tumor necrosis factor blocker	749	0.1%
Skyrizi	Interleukin-23 antagonist	649	0.8%
Xeljanz	Janus kinase inhibitor	534	0.3%
Dupixent	Interleukin-4 receptor alpha antagonist	440	0.1%
Oxycodone hydrochloride	Opioid agonist	292	0.3%
OxyContin	Opioid agonist	272	0.2%
Xyrem	Central nervous system depressant	237	0.4%
Forteo	Parathyroid hormone analog	213	0.2%
Prolia	RANK ligand inhibitor	213	0.2%
Imbruvica	Kinase inhibitor	205	0.3%
Repatha	PCSK9 inhibitor	149	0.1%
Certolizumab pegol	Tumor necrosis factor blocker	113	0.4%
Avonex	Interferon beta	111	0.1%
Ozempic	GLP-1 receptor agonist	110	0.2%
Hydrocodone bitartrate and acetaminophen	Opioid agonist	109	0.2%
Simponi	Tumor necrosis factor blocker	109	0.2%
Cimzia	Tumor necrosis factor blocker	107	0.1%
Creon	—	102	0.5%
Dilaudid	Opioid agonist	101	0.2%
Methotrexate	Folate analog metabolic inhibitor	99	0%
Oxycodone and acetaminophen	Opioid agonist	97	0.4%
Morphine sulfate	Opioid agonist	96	0.2%
Otezla	Phosphodiesterase 4 inhibitor	91	0.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Janus kinase inhibitor	1,586	0.5%	0%
Opioid agonist	1,570	0.2%	0.1%
Tumor necrosis factor blocker	1,209	0.1%	0%
Interleukin-23 antagonist	688	0.6%	0%
Interleukin-4 receptor alpha antagonist	467	0.1%	0.2%
Kinase inhibitor	344	0%	0%
Central nervous system depressant	318	0.4%	0.6%
Parathyroid hormone analog	226	0.2%	0.2%
RANK ligand inhibitor	223	0.1%	0%
Corticosteroid	193	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20%4

2 to 110.3%35

12 to 170.3%41

18 to 444.2%498

45 to 6427.2%3,255

65 to 7419.6%2,342

75 and over9.2%1,096

Age not given39.1%4,675

Patient sex

Female61.4%7,332

Male32.2%3,845

Not given6.4%769

Grey bar: all 20,646,523 reports in the database. 87.6% of these reports give the United States as the country.

Questions about "Spinal operation"

What does "Spinal operation" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record spinal operation?

11,946 reports through June 2026 (0.1% of all reports), 1,356 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humira (1,092), Rinvoq (1,036), Enbrel (749), Skyrizi (649) and Xeljanz (534). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.